Rimonabant Acomplia Review
Now that a promising new prescription anti-obesity drug, Rimonabant Acomplia, is actually available in the U.K., Germany and several other countries, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans.
The drug, marketed in Europe as Acomplia, ultimately is expected to reach the United States under the name Zimulti. Whatever the trade name, Rimonabant Acomplia has been hailed by some doctors on the basis of clinical trials as a major breakthrough in treating obesity.
PHASE III DATA HIGHLIGHT EFFICACY AND SAFETY
The promising preclinical findings with Rimonabant Acomplia have been confirmed in a series of clinical studies, including pivotal phase III trials involving over 6,000 obese subjects that were carried out in both the US and Europe.
Two-year data from the phase III multicentre Rimonabant Acomplia In Obesity (RIO) trials, which compared rimonabant at doses of 5mg and 20mg with placebo with respect to weight reduction and prevention of weight gain, showed that the positive results seen after a year's treatment were sustained over the full two-year trial period.
"There is a strong association between obesity and increased risk of cardiovascular disease, diabetes and possibly certain cancers."
Consistent with the one-year data, the results showed that overweight and obese patients taking rimonabant 20mg/d achieved significant reductions in body weight, waist circumference (an indicator of abdominal obesity) and improved lipid and glycaemic profiles compared with placebo recipients. Rimonabant also had a significant impact on metabolic CVD risk factors, greater than that expected by weight loss alone.
Learn more about Rimonabant (Acomplia)
Where to buy Rimonabant Acomplia
To buy Rimonabant (Acomplia) click here: Buy Rimonabant (Acomplia)
Review of other weightloss pills: Tenuate 75mg, Obelit, Stimerex, Meridia Reviews
If know more useful resources, please contact me (via comments of this blog).
Have a good week!
